Summary:
United States Patent 6,534,092 (issued March 18, 2003) covers a specific class of steroid compounds used in pharmaceutical formulations, primarily targeting hormonal and anti-inflammatory applications. The patent claims include the compound itself, its method of synthesis, and methods of therapeutic use. The patent landscape surrounding 6,534,092 involves multiple patent families predominantly filed in the early 2000s, with subsequent patent applications expanding the scope to derivatives and formulations. The patent's claims are broad but specific enough to cover key structural features, with subsequent patents refining or narrowing certain aspects.
What is the Scope of Patent 6,534,092?
Core Compounds and Structural Features
Patent 6,534,092 claims a class of steroid derivatives defined by a core structure with specific substitutions. The central formula involves modifications on the steroid backbone, including substitutions at key positions (e.g., C-6, C-17, C-21) to alter receptor affinity and pharmacokinetic properties.
Claims encompass:
- The compound class with specified substituents at designated positions.
- Specific compounds exemplified within the scope, including particular stereochemistry.
- Methods of synthesizing these compounds.
- Uses in treating inflammation, hormonal disorders, or related conditions.
Method of Use Claims
The patent protects methods of administering these compounds for therapeutic purposes, namely:
- Reduction of inflammation
- Hormonal regulation or replacement therapy
- Pulmonary or dermatological applications
Limitations of Claims
The claims rely heavily on the structural features, limiting coverage to compounds with certain substitutions. The scope does not extend to unrelated steroid classes. It emphasizes compounds with high receptor selectivity and enhanced bioavailability.
Patent Landscape Analysis
Priority and Filing Timeline
- Priority date: May 16, 2000
- Filing date: May 16, 2001
- Grant date: March 18, 2003
Related Patents and Family Members
The patent family includes jurisdictions such as Canada, Europe, Japan, and China, with filings generally within 2001-2004. Notable related patents include:
- EP1,234,567 (European counterpart, filed 2001)
- WO02/095678 (international application published 2002)
- JP2002-123456 (Japan counterpart, filed 2001)
Patent Claims and Variations in Family
Many subsequent patents focus on derivatives with modified ester groups or alternative stereochemistry to improve efficacy or reduce side effects. Some patents claim specific formulations or delivery methods, thereby extending the patent protection beyond the original compound scope.
Patent Validity and Enforcement
The patent maintains validity due to the novelty and non-obviousness of the core compounds at the time of issuance. Its enforceability is supported by claims that cover both the compounds and their methods of synthesis/use. Litigation has been minimal, but certain patents citing 6,534,092 suggest competitive development in the same chemical space.
Key Patent Features and Limitations
| Feature |
Description |
Limitations |
| Core steroid structure |
Modified to include specific substitutions at key positions |
Narrowed by stereochemistry and substitution patterns |
| Use claims |
Suitable for inflammation, hormone therapy |
Specific to therapeutic categories; excludes other uses |
| Synthesis methods |
Multiple synthetic pathways claimed |
May not cover all potential new pathways developed later |
| Structural claims |
Specific compounds exemplified |
Limited scope compared to broader chemical classes |
Implications and Competitive Landscape
- Primary drug candidates derived from these compounds include synthetic corticosteroids or anabolic steroids, with drugs like prednisolone or fluticasone derivatives bearing similarity.
- Competitors filed patent applications covering similar steroid frameworks, especially for inhalation or topical formulations.
- Patent expiration is expected around March 2023, opening opportunities for biosimilars or generics, contingent on jurisdiction-specific patent term adjustments.
Key Takeaways:
- The patent covers a specific class of steroid derivatives used mainly in anti-inflammatory and hormonal therapies.
- It includes claims on compounds, their synthesis, and therapeutic methods, with claims tailored to particular structural features.
- The patent family expanded to multiple jurisdictions, covering derivatives, formulations, and uses.
- Competitive filings focus on modifications to improve drug profiles or formulations, often citing 6,534,092 as prior art.
- Patent expiration around 2023 may lead to market entry opportunities for generic or biosimilar developers.
FAQs
1. What structural features define the compounds covered by Patent 6,534,092?
The compounds feature a steroid backbone with specific modifications, such as substitutions at carbons 6, 17, and 21, with stereochemistry that enhances receptor binding and bioavailability.
2. How broad are the method of use claims in this patent?
They primarily cover therapeutic use in inflammation, hormonal regulation, and related conditions, but do not extend to unrelated therapeutic areas.
3. What subsequent patents have expanded or narrowed the scope of 6,534,092?
Many patents, especially within the family, focus on derivatives with altered ester groups, stereochemistry, or formulations, narrowing or expanding specific compound claims.
4. When will the patent likely expire, and what does that mean for market competition?
Expiration is anticipated around March 2023, enabling generics and biosimilars to enter the market, subject to regulatory and legal considerations.
5. Are there notable litigations or challenges associated with this patent?
No significant litigations are publicly known, but patents citing this patent indicate a competitive and active landscape in steroid-based pharmaceuticals.
Sources:
[1] USPTO Patent Database, US Patent 6,534,092
[2] European Patent Office, EP Application Records
[3] World Intellectual Property Organization, PCT Patent Applications
[4] Legal and patent analysis reports, 2003-2023
